Peptide Initiative

Dosing protocol · Healing & Recovery

Ziconotide (Prialt) dosing & administration

FDA-approved intrathecal analgesic derived from cone snail venom for severe chronic pain

Suggested dose

2.4 – 19.2 mcg/day

Continuous intrathecal infusionFrequency
IntrathecalRoute
Ongoing/indefiniteCycle length

Dosing

How much Ziconotide (Prialt) do I take?

Intrathecal

Intrathecal: Infused into the fluid around the spinal cord, done in a hospital by a specialist.

Bioavailability Acts directly on the spinal cord/brain fluid — bypasses the bloodstream entirely.

Titration schedule

  • point

    2.4 mcg/day

    Frequency
    Continuous infusion
    Duration
    Starting point

    Ziconotide is pumped directly into the fluid around the spinal cord, using an implanted or external microinfusion device — it is NOT for intravenous administration . The label starts at no more than 2.4 mcg per day (0.1 mcg per hour) . Starting low matters here more than usual: the boxed warning is for severe psychiatric symptoms and neurological impairment, and the drug is contraindicated in anyone with a history of psychosis .

  • Until pain is controlled

    Increase up to 2.4 mcg/day per step

    Frequency
    No more than 2-3 times per week
    Duration
    Until pain is controlled

    The dose is raised by up to 2.4 mcg per day at a time, no more often than 2 to 3 times a week . This is one of the few genuine titrations in this library: the same patient climbs the ladder, rather than different patients being assigned different rungs. What you are titrating against is not just pain — the label directs frequent monitoring for cognitive impairment, hallucinations and changes in mood or consciousness, and discontinuation if serious neurological or psychiatric signs appear .

  • Ongoing/maintenance

    Up to 19.2 mcg/day

    Frequency
    Continuous infusion
    Duration
    Ongoing/maintenance

    The recommended maximum is 19.2 mcg per day (0.8 mcg per hour), reached by about day 21 on the label's schedule . Many people settle below it. Reported psychiatric events at clinical doses include hallucinations in 12%, paranoid reactions in 3%, hostility in 2%, delirium in 2%, psychosis in 1% and manic reactions in 0.4% — and the placebo-controlled trials found a higher incidence of suicide, suicide attempts and suicidal ideation on ziconotide than on placebo . Slower is better tolerated than faster, and the ceiling is a ceiling, not a target.

Timing

Best time to take

Use Ziconotide (Prialt) at the same time each day for optimal results. Consistency in timing helps maintain stable levels and maximize therapeutic benefits. Follow your healthcare provider's specific instructions.

With food?

Ziconotide (Prialt) can generally be used with or without food. If you experience any discomfort, try taking it with a light meal. Follow specific guidance from your healthcare provider.

If stacking

Ziconotide (Prialt) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

Adjusting your dose

Increase if

  • You've tolerated the current dose for the recommended period without significant side effects
  • Therapeutic goals haven't been met at the current dose level
  • Your healthcare provider recommends dose escalation based on your response
  • Lab work or clinical assessments support a higher dose

Decrease if

  • Side effects are bothersome or impacting daily life despite management strategies
  • You experience any signs of an adverse reaction
  • Lab results indicate the need for dose reduction
  • Your healthcare provider recommends a lower dose based on your response

Signs of right dose

  • Therapeutic goals being met with minimal side effects
  • Stable and consistent response to treatment
  • Lab values or clinical markers trending in the right direction
  • Good tolerance with manageable or absent side effects

Administration

How do I use Ziconotide (Prialt)?

Reconstitution

What you need

  • Ziconotide (Prialt) vial (lyophilized powder or solution)
  • Bacteriostatic water or sterile sodium chloride for reconstitution
  • Alcohol swabs for cleaning vial tops and injection sites
  • Appropriately sized syringes with fine-gauge needles (27-30 gauge)
  • Sharps disposal container

Injection

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

Storage

Before reconstitution

Store Ziconotide (Prialt) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After reconstitution

Once reconstituted, Ziconotide (Prialt) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation — discard the vial

  • Solution appears cloudy, discolored, or contains visible particles (should be clear)
  • Product has been exposed to temperatures outside the recommended storage range
  • Product has been frozen (unless specifically designed for freeze-thaw stability)
  • Expiration date has passed or reconstituted solution has exceeded its use-by date
  • Unusual odor, color change, or visible contamination

Sample daily schedule

  • As prescribed (once daily)

    As prescribed by your healthcare provider injection

    Site: Intrathecal infusion—rotate sites if applicable

    Maintain a consistent schedule for optimal results with Ziconotide (Prialt). Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

Safety

Is Ziconotide (Prialt) safe?

Side effects

Commonly reported: Dizziness, Nausea

Less common: Confusion and Memory Impairment, Ataxia and Nystagmus

Serious side effects

  • Psychiatric Symptoms
  • Elevated Creatine Kinase and Rhabdomyolysis
  • Psychiatric Symptoms
  • Rhabdomyolysis with Acute Renal Failure

Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Ziconotide (Prialt)
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Ziconotide (Prialt) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

Flagged pairings

  • CNS Depressants — May potentiate central nervous system depression including somnolence and confusion
  • Intrathecal Opioids — Concurrent intrathecal opioids increase risk of serious adverse events including respiratory depression
  • Psychotropic Medications — May exacerbate psychiatric adverse effects including hallucinations and psychosis risk

Published research

What the studies show

  • Strong human trials (Phase 3 or FDA approved)
  • FDA approved (PRIALT, 2004) for the management of severe chronic pain in adults for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatment, including intrathecal morphine. Carries a BOXED WARNING for neuropsychiatric adverse reactions and is contraindicated in anyone with a pre-existing history of psychosis.
  1. Efficacy and safety of Cav2.2 blocker Ziconotide in pain: meta-analysis and systematic review

    Picañol J, et al. · 2025PubMed

    Meta-analysis of ziconotide showed significant pain reduction (22.54-point improvement) versus placebo with 17.85% serious adverse events. Secondary outcomes suggest potential opioid sparing, though evidence quality was moderate.

  2. Can Ziconotide Be Used to Replace Opioids? Clinical Experience in 5 Patients

    Canovas Martínez L, et al. · 2025PubMed

    Five patients successfully reduced morphine doses by 50% after 6 weeks of ziconotide titration while achieving pain reduction from 8.0 to 2.5. Neuropathic symptoms improved dramatically with 80% reduction in tingling.

  3. Selecting Neuromodulation Devices For Chronic Pain Conditions: A Narrative Review

    Wahezi S, et al. · 2026PubMed

    A narrative review established ziconotide as a selective Cav2.2 channel blocker offering precise pain relief through intrathecal delivery for refractory chronic pain. Combined with morphine, it reduced opioid requirements.

  4. Ziconotide as an Opioid Rescue: Economic, Clinical, and Subgroup Considerations

    Gan H, et al. · 2025PubMed

    No abstract available for comprehensive analysis.

  5. Recurrent Ziconotide-Associated Delirium and Psychosis: A Case Report

    Noe G, et al. · 2025PubMed

    No abstract available for comprehensive analysis.

  6. PRIALT (ziconotide intrathecal infusion) Prescribing Information

    TerSera / U.S. FDA · 2023accessdata.fda.gov

    PRIALT is delivered only by intrathecal infusion. Start at no more than 2.4 mcg/day (0.1 mcg/hr) and titrate in increments of up to 2.4 mcg/day no more than 2 to 3 times per week, based on response and side effects, to a maximum of 19.2 mcg/day (0.8 mcg/hr).

Head to head

Ziconotide (Prialt) compared

Studied for

Conditions Ziconotide (Prialt) has been researched in

Want the full picture?

The complete Ziconotide (Prialt) research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.